Table 3.
Major phase III clinical trials combining PARP inhibitors with immunotherapy.
| Drug | Cancer | Immunotherapy | Trial ID | Identifier |
|---|---|---|---|---|
| Olaparib | Ovarian cancer | Pembrolizusmab | ENGOT-OV43/KEYLYNK-001 | NCT03740165 |
| Ovarian cancer | Durvalumab | DUO-O | NCT03737643 | |
| Endometrial cancer | Durvalumab | DUO-E | NCT04269200 | |
| TNBC | Pembrolizumab | KEYLYNK-009 | NCT04191135 | |
| NSCLC | Pembrolizumab | KEYLYNK-006 | NCT03976323 | |
| NSCLC | Pembrolizumab | KEYLYNK-012 | NCT04380636 | |
| NSCLC | Pembrolizumab | KEYLYNK-008 | NCT03976362 | |
| mCRPC | Pembrolizumab | KEYLYNK-010 | NCT03834519 | |
| Talazoparib | Ovarian cancer | Avelumab | JAVELIN ovarian PARP 100 | NCT03642132 |
| Niraparib | Ovarian cancer | Dostarlimab | ENGOT-0V44/FIRST | NCT03602859 |
| Ovarian, fallopian tube or primary peritoneal cancer | Dostarlimab | NItCHE-MITO33 | NCT04679064 | |
| Ovarian, tubal or peritoneal cancer | Atezolizumab | ANITA | NCT03598270 | |
| Ovarian carcinosarcoma | Dostarlimab | ROCSAN | NCT03651206 | |
| Endometrial cancer | Dostarlimab | RUBY part 2 | NCT03981796 | |
| NSCLC | Pembrolizumab | ZEAL-1L | NCT04475939 | |
| Rucaparib | Ovarian cancer | Nivolumab | ATHENA | NCT03522246 |
mCRPC, metastatic castration-resistant prostate cancer; NSCLC, non-small cell lung cancer; TNBC, triple negative breast cancer.